[go: up one dir, main page]

WO2004011489A3 - Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes - Google Patents

Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes Download PDF

Info

Publication number
WO2004011489A3
WO2004011489A3 PCT/FR2003/002315 FR0302315W WO2004011489A3 WO 2004011489 A3 WO2004011489 A3 WO 2004011489A3 FR 0302315 W FR0302315 W FR 0302315W WO 2004011489 A3 WO2004011489 A3 WO 2004011489A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphocytes
adenovirus
fiber
tropism
cells
Prior art date
Application number
PCT/FR2003/002315
Other languages
English (en)
Other versions
WO2004011489A2 (fr
Inventor
Halluin Jean Claude D
Laurence Renaut
Morvane Colin
Original Assignee
Inst Nat Sante Rech Med
Halluin Jean Claude D
Laurence Renaut
Morvane Colin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Halluin Jean Claude D, Laurence Renaut, Morvane Colin filed Critical Inst Nat Sante Rech Med
Priority to AU2003273463A priority Critical patent/AU2003273463A1/en
Publication of WO2004011489A2 publication Critical patent/WO2004011489A2/fr
Publication of WO2004011489A3 publication Critical patent/WO2004011489A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des adénovirus recombinants dont le tropisme a été modifié pour leur permettre d'infecter des lymphocytes B ou des cellules d'ovaire. Les adénovirus recombinants selon la présente invention présente un tropisme réduit par rapport à celui de l'adénovirus natif. Elle concerne également des méthodes pour la préparation de tels adénovirus, ainsi que leurs utilisations, notamment pour le transfert de séquences d'ADN dans des lymphocytes B ou des cellules d'ovaire in vitro, ex vivo ou in vivo, dans un but expérimental, industriel, vaccinal ou thérapeutique. L'invention décrit plus spécifiquement la modification du gène de la fibre de l'adénovirus dans le but de cibler des lymphocytes B ou des cellules ovariennes, en particulier des cellules tumorales, ainsi que d'autres modifications et/ou constructions permettant de conférer aux virus un caractère spécifique pour ces cellules. L'invention est caractérisée notamment soit par l'introduction dans la fibre de la séquence d'un peptide reconnaissant un récepteur exprimé à la surface des lymphocytes B, soit par le remplacement du bouton de la fibre d'un adénovirus Mastadenovirus par un bouton de la fibre d'un adénovirus phylogéniquement éloigné, de préférence de l'adénovirus bovin de sérotype 4 (BAV4).
PCT/FR2003/002315 2002-07-25 2003-07-22 Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes WO2004011489A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273463A AU2003273463A1 (en) 2002-07-25 2003-07-22 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209426A FR2842823A1 (fr) 2002-07-25 2002-07-25 Adenovirus modifies pour le ciblage des lymphocytes b
FR02/09426 2002-07-25

Publications (2)

Publication Number Publication Date
WO2004011489A2 WO2004011489A2 (fr) 2004-02-05
WO2004011489A3 true WO2004011489A3 (fr) 2004-07-01

Family

ID=30011465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002315 WO2004011489A2 (fr) 2002-07-25 2003-07-22 Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes

Country Status (3)

Country Link
AU (1) AU2003273463A1 (fr)
FR (1) FR2842823A1 (fr)
WO (1) WO2004011489A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709209A2 (pt) * 2006-03-28 2011-06-28 Procter & Gamble processo de redução de hidreto para preparo de intermediários de quinolona

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006826A1 (fr) * 1995-08-14 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Therapie genique utilisant des vecteurs d'adenovirus ovins
WO1998040508A1 (fr) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Vecteurs adenoviraux a modification du tropisme
WO1998054346A1 (fr) * 1997-05-28 1998-12-03 Genvec, Inc. Adenovirus a ciblage alternatif
WO1999047180A1 (fr) * 1998-03-20 1999-09-23 Genzyme Corporation Vecteurs adenoviraux chimeres pour apport cible de genes
WO2000073478A2 (fr) * 1999-06-01 2000-12-07 University Of Washington Vecteurs adenoviraux recombinants pour l'infection specifique de cellules, l'integration de genomes et l'expression de proteines fibreuses chimeriques
WO2001092547A2 (fr) * 2000-05-31 2001-12-06 University Of Saskatchewan Adenovirus bovin modifie avec modification du tropisme

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006826A1 (fr) * 1995-08-14 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Therapie genique utilisant des vecteurs d'adenovirus ovins
WO1998040508A1 (fr) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Vecteurs adenoviraux a modification du tropisme
WO1998054346A1 (fr) * 1997-05-28 1998-12-03 Genvec, Inc. Adenovirus a ciblage alternatif
WO1999047180A1 (fr) * 1998-03-20 1999-09-23 Genzyme Corporation Vecteurs adenoviraux chimeres pour apport cible de genes
WO2000073478A2 (fr) * 1999-06-01 2000-12-07 University Of Washington Vecteurs adenoviraux recombinants pour l'infection specifique de cellules, l'integration de genomes et l'expression de proteines fibreuses chimeriques
WO2001092547A2 (fr) * 2000-05-31 2001-12-06 University Of Saskatchewan Adenovirus bovin modifie avec modification du tropisme

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CURIEL D T: "STRATEGIES TO ADAPT ADENOVIRAL VECTORS FOR TARGETED DELIVERY", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 886, 1999, pages 158 - 171, XP000979449, ISSN: 0077-8923 *
DAN ADAM ET AL: "Analysis of the hexon gene sequence of bovine adenovirus type 4 provides further support for a new adenovirus genus (Atadenovirus)", JOURNAL OF GENERAL VIROLOGY, vol. 79, no. 6, June 1998 (1998-06-01), pages 1453 - 1460, XP002276148, ISSN: 0022-1317 *
DATABASE GENBANK [online] NCBI; 16 April 2001 (2001-04-16), DAN A ET AL.: "Bovine Adenovirus 4", XP002276150, Database accession no. AF036092 *
HESS MICHAEL ET AL: "The complete nucleotide sequence of the egg drop syndrome virus: An intermediate between mastadenoviruses and aviadenoviruses", VIROLOGY, vol. 238, no. 1, 10 November 1997 (1997-11-10), pages 145 - 156, XP004460036, ISSN: 0042-6822 *
ISRAEL BRUCE F ET AL: "Enhancement of adenovirus vector entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody", JOURNAL OF VIROLOGY, vol. 75, no. 11, June 2001 (2001-06-01), pages 5215 - 5221, XP002265173, ISSN: 0022-538X *
KIRBY I ET AL: "MUTATIONS IN THE DG LOOP OF ADENOVIRUS TYPE 5 FIBER KNOB PROTEIN ABOLISH HIGH-AFFINITY BINDING TO ITS CELLULAR RECEPTOR CAR", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 11, November 1999 (1999-11-01), pages 9508 - 9514, XP000984778, ISSN: 0022-538X *
KRASNYKH VICTOR ET AL: "Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 9, May 2001 (2001-05-01), pages 4176 - 4183, XP002202288, ISSN: 0022-538X *
SEGERMAN A ET AL: "Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 3, February 2000 (2000-02-01), pages 1457 - 1467, XP002161682, ISSN: 0022-538X *
SEGGERN VON D J ET AL: "ADENOVIRUS VECTOR PSEUDOTYPING IN FIBER-EXPRESSING CELL LINES: IMPROVED TRANSDUCTION OF EPSTEIN-BARR VIRUS-TRANSFORMED B CELLS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 1, January 2000 (2000-01-01), pages 354 - 362, XP000906911, ISSN: 0022-538X *
WICKHAM T J ET AL: "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 11, 1 November 1997 (1997-11-01), pages 8221 - 8229, XP002078898, ISSN: 0022-538X *
WICKHAM T J: "TARGETING ADENOVIRUS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 2, January 2000 (2000-01-01), pages 110 - 114, XP001055892, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
AU2003273463A1 (en) 2004-02-16
WO2004011489A2 (fr) 2004-02-05
FR2842823A1 (fr) 2004-01-30
AU2003273463A8 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
IL152420A0 (en) Novel oncolytic adenoviral vectors
CA2477954A1 (fr) Moyens et procede de production de vecteurs d'adenovirus
WO2010086189A3 (fr) Séquences d'acide aminé et d'acide nucléique d'adénovirus simien, vecteurs les contenant, et utilisations afférentes
EP2325298A3 (fr) Adenovirus de singe SAdV-36, -42.1, -42.2, AND -44 et leur utilisation
WO2006127956A3 (fr) Systeme destine a la production rapide de vecteurs d'adenovirus recombinants exempts d'adenovirus, a titre eleve et a competence de replication
IS4754A (is) Genaferjur og aðferðir fyrir genaflutning inn í frumur
WO2008084115A3 (fr) Promoteurs lactococcus et leurs utilisations
WO2010138263A3 (fr) Nouveaux virus adéno-associés (aav) et leurs utilisations
DK1349926T3 (da) Komplementerende cellelinier
WO2005001103A3 (fr) Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
WO2005118825A3 (fr) Adenovirus chimeres a utiliser dans le traitement du cancer
WO2006096815A3 (fr) Promoteur htmc et vecteurs destines a l'expression hautement efficace et selective pour une tumeur de genes therapeutiques contre le cancer
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
BR9908018A (pt) Adenovìrus modificado contendo uma proteìna de substituição de fibra
WO2006119449A3 (fr) Adenovirus modifie contenant un anticorps stabilise
WO2006039045A3 (fr) Methode d'utilisation de vecteurs adenoviraux presentant une immunogenicite accrue in vivo
WO2006110240A3 (fr) Transfert de genes au moyen d'adenovirus presentant des proteines fibres modifiees
RU2006132340A (ru) Слитые белки карциноэмбрионального антигена
Nettelbeck Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis
WO2003029433A3 (fr) Vecteurs viraux chimeres destines a une therapie genique
WO2006086357A3 (fr) Vecteurs adenoviraux de serotype 36, acides nucleiques et virus ainsi produits
EP1539937A4 (fr) Methodes de propagation d'adenovirus et virus ainsi obtenu
WO2004011489A3 (fr) Adenovirus modifies pour changer leur tropisme, de preference pour le ciblage des lymphocytes b ou des cellules ovariennes
WO2001083737A3 (fr) Vaccin d"adenovirus porcin
SI1760153T1 (sl) Adenovirusni/alfavirusni hibridni vektor za uäśinkovito uporabo in ekspresijo terapevtskih genov v tumorskih celicah

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP